Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a ...

The decision to clear another mifepristone generic sparked political backlash. Elsewhere, Medicare delayed a decision on whether to subject “combination” drugs to pricing negotiations, and a cancer ...

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be ...

The company has received a “limited number” of non-binding proposals, mostly from groups of financial investors, for a ...

The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with ...